{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:05:13Z","timestamp":1793275513314,"version":"4.5.0"},"reference-count":204,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005156","name":"Alexander von Humboldt-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>The gut-liver axis covers the bidirectional communication between the gut and the liver, and thus includes signals from liver-to-gut (e.g., bile acids, immunoglobulins) and from gut-to-liver (e.g., nutrients, microbiota-derived products, and recirculating bile acids). In a healthy individual, liver homeostasis is tightly controlled by the mostly tolerogenic liver resident macrophages, the Kupffer cells, capturing the gut-derived antigens from the blood circulation. However, disturbances of the gut-liver axis have been associated to the progression of varying chronic liver diseases, such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and primary sclerosing cholangitis. Notably, changes of the gut microbiome, or intestinal dysbiosis, combined with increased intestinal permeability, leads to the translocation of gut-derived bacteria or their metabolites into the portal vein. In the context of concomitant or subsequent liver inflammation, the liver is then infiltrated by responsive immune cells (e.g., monocytes, neutrophils, lymphoid, or dendritic cells), and microbiota-derived products may provoke or exacerbate innate immune responses, hence perpetuating liver inflammation and fibrosis, and potentiating the risks of developing cirrhosis. Similarly, food derived antigens, bile acids, danger-, and pathogen-associated molecular patterns are able to reshape the liver immune microenvironment. Immune cell intracellular signaling components, such as inflammasome activation, toll-like receptor or nucleotide-binding oligomerization domain-like receptors signaling, are potent targets of interest for the modulation of the immune response. This review describes the current understanding of the cellular landscape and molecular pathways involved in the gut-liver axis and implicated in chronic liver disease progression. We also provide an overview of innovative therapeutic approaches and current clinical trials aiming at targeting the gut-liver axis for the treatment of patients with chronic liver and\/or intestinal diseases.<\/jats:p>","DOI":"10.3389\/fmed.2021.725390","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:44:39Z","timestamp":1632789879000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":83,"title":["Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases"],"prefix":"10.3389","volume":"8","author":[{"given":"Alix","family":"Bruneau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Hundertmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Guillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Tacke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/hep4.1356","article-title":"Liver macrophages: old dogmas and new insights","volume":"3","author":"Guillot","year":"2019","journal-title":"Hepatol Commun."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1084\/jem.20160334","article-title":"Identification and treatment of the Staphylococcus aureus reservoir in vivo","volume":"213","author":"Surewaard","year":"2016","journal-title":"J Exp Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrmicro2974","article-title":"The gut microbiota\u2013masters of host development and physiology","volume":"11","author":"Sommer","year":"2013","journal-title":"Nat Rev Microbiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.cmet.2020.09.004","article-title":"The gut microbiota at the service of immunometabolism","volume":"32","author":"Michaudel","year":"2020","journal-title":"Cell Metab."},{"key":"B5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1872-034X.2012.01088.x","article-title":"Role of gut microbiota in liver diseases","volume":"43","author":"Miyake","year":"2013","journal-title":"Hepatol Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J Hepatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"aaw4361","DOI":"10.1126\/science.aaw4361","article-title":"Laboratory mice born to wild mice have natural microbiota and model human immune responses","volume":"365","author":"Rosshart","year":"2019","journal-title":"Science."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.cell.2017.09.016","article-title":"Wild mouse gut microbiota promotes host fitness and improves disease resistance","volume":"171","author":"Rosshart","year":"2017","journal-title":"Cell."},{"key":"B9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nature13568","article-title":"Alterations of the human gut microbiome in liver cirrhosis","volume":"513","author":"Qin","year":"2014","journal-title":"Nature."},{"key":"B10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.hbpd.2020.01.003","article-title":"Human microbiome is a diagnostic biomarker in hepatocellular carcinoma","volume":"19","author":"Rao","year":"2020","journal-title":"Hepatobiliary Pancreat Dis Int."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.3389\/fimmu.2018.02418","article-title":"Adapted immune responses of myeloid-derived cells in fatty liver disease","volume":"9","author":"Hundertmark","year":"2018","journal-title":"Front Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.femsre.2004.09.003","article-title":"The interaction between bacteria and bile","volume":"29","author":"Begley","year":"2005","journal-title":"FEMS Microbiol Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/s41385-019-0162-4","article-title":"Emerging roles of bile acids in mucosal immunity and inflammation","volume":"12","author":"Chen","year":"2019","journal-title":"Mucosal Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/nature09944","article-title":"Enterotypes of the human gut microbiome","volume":"473","author":"Arumugam","year":"2011","journal-title":"Nature."},{"key":"B15","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/nature11552","article-title":"Functional interactions between the gut microbiota and host metabolism","volume":"489","author":"Tremaroli","year":"2012","journal-title":"Nature."},{"key":"B16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/nu7010017","article-title":"The impact of diet and lifestyle on gut microbiota and human health","volume":"7","author":"Conlon","year":"2014","journal-title":"Nutrients."},{"key":"B17","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1136\/gutjnl-2016-313332","article-title":"Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy","volume":"67","author":"Tang","year":"2018","journal-title":"Gut."},{"key":"B18","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1136\/gutjnl-2015-310500","article-title":"The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls","volume":"66","author":"Kummen","year":"2017","journal-title":"Gut."},{"key":"B19","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1136\/gutjnl-2016-311915","article-title":"The gut-adherent microbiota of PSC-IBD is distinct to that of IBD","volume":"66","author":"Quraishi","year":"2017","journal-title":"Gut."},{"key":"B20","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1093\/ecco-jcc\/jju023","article-title":"The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II","volume":"9","author":"Rossen","year":"2015","journal-title":"J Crohns Colitis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1177\/2050640617708953","article-title":"The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease","volume":"6","author":"Torres","year":"2018","journal-title":"United European Gastroenterol J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1136\/gutjnl-2015-311004","article-title":"Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD","volume":"65","author":"Sabino","year":"2016","journal-title":"Gut."},{"key":"B23","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.3748\/wjg.v23.i25.4548","article-title":"Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis","volume":"23","author":"Bajer","year":"2017","journal-title":"World J Gastroenterol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1136\/gutjnl-2019-320008","article-title":"Gut mycobiome of primary sclerosing cholangitis patients is characterised by an increase of Trichocladium griseum and Candida species","volume":"69","author":"Ruhlemann","year":"2020","journal-title":"Gut."},{"key":"B25","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1136\/gutjnl-2018-317791","article-title":"Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis","volume":"69","author":"Lemoinne","year":"2020","journal-title":"Gut."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1172\/JCI90562","article-title":"Intestinal fungi contribute to development of alcoholic liver disease","volume":"127","author":"Yang","year":"2017","journal-title":"J Clin Invest."},{"key":"B27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s40168-017-0359-2","article-title":"Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease","volume":"5","author":"Dubinkina","year":"2017","journal-title":"Microbiome."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell Metab."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1053\/j.gastro.2020.07.005","article-title":"Intestinal virome signature associated with severity of nonalcoholic fatty liver disease","volume":"159","author":"Lang","year":"2020","journal-title":"Gastroenterology."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1111\/liv.14899","article-title":"Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy-proven non-alcoholic fatty liver disease","volume":"41","author":"Lang","year":"2021","journal-title":"Liver Int."},{"key":"B31","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/hep4.1509","article-title":"High protein intake is associated with histological disease activity in patients with NAFLD","volume":"4","author":"Lang","year":"2020","journal-title":"Hepatol Commun."},{"key":"B32","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e62885","DOI":"10.1371\/journal.pone.0062885","article-title":"Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis\u2013a longitudinal study","volume":"8","author":"Wong","year":"2013","journal-title":"PLoS ONE."},{"key":"B34","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/hep.26093","article-title":"Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH","volume":"57","author":"Zhu","year":"2013","journal-title":"Hepatology."},{"key":"B35","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.jhep.2013.01.003","article-title":"Modulation of the fecal bile acid profile by gut microbiota in cirrhosis","volume":"58","author":"Kakiyama","year":"2013","journal-title":"J Hepatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jhep.2013.12.019","article-title":"Altered profile of human gut microbiome is associated with cirrhosis and its complications","volume":"60","author":"Bajaj","year":"2014","journal-title":"J Hepatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e0197319","DOI":"10.1371\/journal.pone.0197319","article-title":"Molecular quantification and differentiation of Candida species in biological specimens of patients with liver cirrhosis","volume":"13","author":"Krohn","year":"2018","journal-title":"PLoS ONE."},{"key":"B38","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/hep.30036","article-title":"Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease","volume":"69","author":"Ponziani","year":"2019","journal-title":"Hepatology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/j.transproceed.2016.01.077","article-title":"Profile of gut microbiota associated with the presence of hepatocellular cancer in patients with liver cirrhosis","volume":"48","author":"Grat","year":"2016","journal-title":"Transplant Proc."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1136\/jcp.2004.018556","article-title":"Identification of helicobacter species in human liver samples from patients with primary hepatocellular carcinoma","volume":"57","author":"Huang","year":"2004","journal-title":"J Clin Pathol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.autrev.2017.07.002","article-title":"Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases","volume":"16","author":"Li","year":"2017","journal-title":"Autoimmun Rev."},{"key":"B42","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1055\/s-0036-1594007","article-title":"The Microbiome And Primary Sclerosing Cholangitis","volume":"36","author":"Ali","year":"2016","journal-title":"Semin Liver Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.4049\/jimmunol.1800711","article-title":"Colitis promotes a pathological condition of the liver in the absence of Foxp3(+) Regulatory T cells","volume":"201","author":"Mathies","year":"2018","journal-title":"J Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1053\/j.gastro.2018.02.019","article-title":"Alterations in intestinal microbiota lead to production of interleukin 17 by intrahepatic gammadelta T-Cell receptor-positive cells and pathogenesis of cholestatic liver disease","volume":"154","author":"Tedesco","year":"2018","journal-title":"Gastroenterology."},{"key":"B45","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/TP.0000000000002484","article-title":"Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: implications for liver transplantation","volume":"103","author":"Younossi","year":"2019","journal-title":"Transplantation."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.3390\/jcm9082648","article-title":"Liver steatosis, gut-liver axis, microbiome and environmental factors. a never-ending bidirectional cross-talk","volume":"9","author":"Di Ciaula","year":"2020","journal-title":"J Clin Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s00018-019-03011-w","article-title":"The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD)","volume":"76","author":"Safari","year":"2019","journal-title":"Cell Mol Life Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1136\/gut.48.2.206","article-title":"The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis","volume":"48","author":"Wigg","year":"2001","journal-title":"Gut."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1007\/s10620-010-1447-3","article-title":"Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8","volume":"56","author":"Shanab","year":"2011","journal-title":"Dig Dis Sci."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1007\/s10620-015-3776-8","article-title":"Altered bile acid metabolome in patients with nonalcoholic steatohepatitis","volume":"60","author":"Ferslew","year":"2015","journal-title":"Dig Dis Sci."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S0140-6736(18)31310-2","article-title":"Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"392","author":"Collaborators","year":"2018","journal-title":"Lancet."},{"key":"B52","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/S0168-8278(00)80242-1","article-title":"Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease","volume":"32","author":"Parlesak","year":"2000","journal-title":"J Hepatol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e53028","DOI":"10.1371\/journal.pone.0053028","article-title":"Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment","volume":"8","author":"Bull-Otterson","year":"2013","journal-title":"PLoS ONE."},{"key":"B54","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/hep.24018","article-title":"Enteric dysbiosis associated with a mouse model of alcoholic liver disease","volume":"53","author":"Yan","year":"2011","journal-title":"Hepatology."},{"key":"B55","doi-asserted-by":"publisher","first-page":"G966","DOI":"10.1152\/ajpgi.00380.2011","article-title":"Colonic microbiome is altered in alcoholism","volume":"302","author":"Mutlu","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41586-019-1742-x","article-title":"Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease","volume":"575","author":"Duan","year":"2019","journal-title":"Nature."},{"key":"B57","doi-asserted-by":"publisher","first-page":"5897","DOI":"10.3748\/wjg.v25.i39.5897","article-title":"Gut-liver axis signaling in portal hypertension","volume":"25","author":"Simbrunner","year":"2019","journal-title":"World J Gastroenterol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ijid.2013.12.014","article-title":"Fungal infection in patients with end-stage liver disease: low frequency or low index of suspicion","volume":"23","author":"Hassan","year":"2014","journal-title":"Int J Infect Dis."},{"key":"B59","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/hep4.1645","article-title":"Loss of coordinated neutrophil responses to the human fungal pathogen, candida albicans, in patients with cirrhosis","volume":"5","author":"Knooihuizen","year":"2021","journal-title":"Hepatol Commun."},{"key":"B60","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.jhep.2012.06.011","article-title":"Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats","volume":"57","author":"Zhang","year":"2012","journal-title":"J Hepatol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/gut.2009.183749","article-title":"Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens","volume":"59","author":"Fox","year":"2010","journal-title":"Gut."},{"key":"B63","doi-asserted-by":"publisher","first-page":"804","DOI":"10.3748\/wjg.15.804","article-title":"Bile acids: chemistry, physiology, and pathophysiology","volume":"15","author":"Monte","year":"2009","journal-title":"World J Gastroenterol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00204-011-0648-7","article-title":"Carcinogenicity of deoxycholate, a secondary bile acid","volume":"85","author":"Bernstein","year":"2011","journal-title":"Arch Toxicol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/hep.31652","article-title":"Bile acid profiles in primary sclerosing cholangitis and their ability to predict hepatic decompensation","volume":"74","author":"Mousa","year":"2020","journal-title":"Hepatology."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e0151829","DOI":"10.1371\/journal.pone.0151829","article-title":"Bile acids and dysbiosis in non-alcoholic fatty liver disease","volume":"11","author":"Mouzaki","year":"2016","journal-title":"PLoS ONE."},{"key":"B67","doi-asserted-by":"publisher","first-page":"154457","DOI":"10.1016\/j.metabol.2020.154457","article-title":"Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression","volume":"116","author":"Nimer","year":"2021","journal-title":"Metabolism."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1002\/ijc.30219","article-title":"Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis","volume":"139","author":"Xie","year":"2016","journal-title":"Int J Cancer."},{"key":"B69","doi-asserted-by":"publisher","first-page":"G929","DOI":"10.1152\/ajpgi.00315.2013","article-title":"Colonic inflammation and secondary bile acids in alcoholic cirrhosis","volume":"306","author":"Kakiyama","year":"2014","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2013.03.013","article-title":"Pleiotropic roles of bile acids in metabolism","volume":"17","author":"de Aguiar Vallim","year":"2013","journal-title":"Cell Metab."},{"key":"B71","doi-asserted-by":"publisher","first-page":"10166","DOI":"10.1038\/ncomms10166","article-title":"Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction","volume":"6","author":"Jiang","year":"2015","journal-title":"Nat Commun."},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1731707","article-title":"Role of FXR in bile acid and metabolic homeostasis in NASH: pathogenetic concepts and therapeutic opportunities","author":"Radun","year":"2021","journal-title":"Semin Liver Dis."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.jhep.2019.08.005","article-title":"Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development","volume":"71","author":"Mouries","year":"2019","journal-title":"J Hepatol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/hep.29359","article-title":"The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids","volume":"67","author":"Puri","year":"2018","journal-title":"Hepatology."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/hep.29857","article-title":"Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism","volume":"68","author":"Pathak","year":"2018","journal-title":"Hepatology."},{"key":"B76","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jcmgh.2021.01.011","article-title":"Circulating bile acids in liver failure activate TGR5 and induce monocyte dysfunction","volume":"12","author":"Leonhardt","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"100230","DOI":"10.1016\/j.jhepr.2021.100230","article-title":"Bile acid-receptor TGR5 deficiency worsens liver injury in alcohol-fed mice by inducing intestinal microbiota dysbiosis","volume":"3","author":"Spatz","year":"2021","journal-title":"JHEP Rep."},{"key":"B78","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.jhep.2021.03.029","article-title":"Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis","volume":"75","author":"Reich","year":"2021","journal-title":"J Hepatol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"13689","DOI":"10.1038\/s41598-017-13102-y","article-title":"Gpbar1 agonism promotes a Pgc-1alpha-dependent browning of white adipose tissue and energy expenditure and reverses diet-induced steatohepatitis in mice","volume":"7","author":"Carino","year":"2017","journal-title":"Sci Rep."},{"key":"B80","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1096\/fj.201801373RR","article-title":"Agonism for the bile acid receptor GPBAR1 reverses liver and vascular damage in a mouse model of steatohepatitis","volume":"33","author":"Carino","year":"2019","journal-title":"FASEB J."},{"key":"B81","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.apsb.2014.12.011","article-title":"Role of farnesoid X receptor and bile acids in alcoholic liver disease","volume":"5","author":"Manley","year":"2015","journal-title":"Acta Pharm Sin B."},{"key":"B82","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nrgastro.2017.119","article-title":"Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis","volume":"15","author":"Jia","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1053\/j.gastro.2017.01.055","article-title":"Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease","volume":"152","author":"Chavez-Talavera","year":"2017","journal-title":"Gastroenterology."},{"key":"B84","doi-asserted-by":"publisher","first-page":"e132305","DOI":"10.1172\/JCI132305","article-title":"Bile acid-activated macrophages promote biliary epithelial cell proliferation through integrin alphavbeta6 upregulation following liver injury","volume":"131","author":"Guillot","year":"2021","journal-title":"J Clin Invest."},{"key":"B85","doi-asserted-by":"publisher","first-page":"11055","DOI":"10.1074\/jbc.M117.784322","article-title":"Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism","volume":"292","author":"Pathak","year":"2017","journal-title":"J Biol Chem."},{"key":"B86","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.3748\/wjg.v25.i17.2019","article-title":"Microbial metabolites in non-alcoholic fatty liver disease","volume":"25","author":"Zhou","year":"2019","journal-title":"World J Gastroenterol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/liv.13979","article-title":"Circulating markers of gut barrier function associated with disease severity in primary sclerosing cholangitis","volume":"39","author":"Dhillon","year":"2019","journal-title":"Liver Int."},{"key":"B88","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.chom.2018.05.003","article-title":"Gut microbiota regulation of tryptophan metabolism in health and disease","volume":"23","author":"Agus","year":"2018","journal-title":"Cell Host Microbe."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1136\/gutjnl-2020-321565","article-title":"Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury","volume":"70","author":"Wrzosek","year":"2020","journal-title":"Gut."},{"key":"B90","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/lt.25994","article-title":"Gut microbial signature of hepatocellular cancer in men with cirrhosis","volume":"27","author":"Albhaisi","year":"2021","journal-title":"Liver Transpl."},{"key":"B91","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1080\/00365521.2021.1880627","article-title":"Associations of neopterin and kynurenine-tryptophan ratio with survival in primary sclerosing cholangitis","volume":"56","author":"Dhillon","year":"2021","journal-title":"Scand J Gastroenterol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1111\/hepr.12876","article-title":"Liver tissue metabolic profiling and pathways of non-alcoholic steatohepatitis in rats","volume":"47","author":"Qi","year":"2017","journal-title":"Hepatol Res."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.immuni.2019.05.023","article-title":"Gut mycobiota in immunity and inflammatory disease","volume":"50","author":"Li","year":"2019","journal-title":"Immunity."},{"key":"B94","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1194\/jlr.R036012","article-title":"The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism","volume":"54","author":"den Besten","year":"2013","journal-title":"J Lipid Res."},{"key":"B95","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.cels.2020.02.008","article-title":"Gut-liver physiomimetics reveal paradoxical modulation of IBD-related inflammation by short-chain fatty acids","volume":"10","author":"Trapecar","year":"2020","journal-title":"Cell Syst."},{"key":"B96","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s12254-020-00597-x","article-title":"The intestinal microbiota and hepatocellular carcinoma","volume":"13","author":"Effenberger","year":"2020","journal-title":"Memo-Mag Eur Med Onc."},{"key":"B97","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1038\/s41467-018-05901-2","article-title":"Microbiota-derived short-chain fatty acids promote Th1 cell IL-10 production to maintain intestinal homeostasis","volume":"9","author":"Sun","year":"2018","journal-title":"Nat Commun."},{"key":"B98","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3109\/08820139.2015.1122613","article-title":"Short-chain fatty acids regulate cytokines and Th17\/Treg cells in human peripheral blood mononuclear cells in vitro","volume":"45","author":"Asarat","year":"2016","journal-title":"Immunol Invest."},{"key":"B99","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41467-020-20422-7","article-title":"Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma","volume":"12","author":"Behary","year":"2021","journal-title":"Nat Commun."},{"key":"B100","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.cell.2018.09.004","article-title":"Dysregulated microbial fermentation of soluble fiber induces cholestatic liver cancer","volume":"175","author":"Singh","year":"2018","journal-title":"Cell."},{"key":"B101","doi-asserted-by":"publisher","first-page":"fnab0386","DOI":"10.1093\/femsle\/fnab038","article-title":"Short-chain fatty acid and fecal microbiota profiles are linked to fibrosis in primary biliary cholangitis","volume":"368","author":"Lammert","year":"2021","journal-title":"FEMS Microbiol Lett."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1101\/gad.1953310","article-title":"Canonical and alternate functions of the microRNA biogenesis machinery","volume":"24","author":"Chong","year":"2010","journal-title":"Genes Dev."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1111\/febs.12806","article-title":"Revisiting the metabolic syndrome and paving the way for microRNAs in non-alcoholic fatty liver disease","volume":"281","author":"Ferreira","year":"2014","journal-title":"FEBS J."},{"key":"B104","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.3748\/wjg.v24.i36.4104","article-title":"Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease","volume":"24","author":"Torres","year":"2018","journal-title":"World J Gastroenterol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/jcmm.12223","article-title":"The functional role of microRNAs in alcoholic liver injury","volume":"18","author":"McDaniel","year":"2014","journal-title":"J Cell Mol Med."},{"key":"B106","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3390\/ijms19010261","article-title":"The role of miRNAs in the pathophysiology of liver diseases and toxicity","volume":"19","author":"Schueller","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B107","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3389\/fmicb.2018.00151","article-title":"Gut microbiota: an integral moderator in health and disease","volume":"9","author":"Feng","year":"2018","journal-title":"Front Microbiol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2147\/CEG.S262879","article-title":"Gut dysbiosis and increased intestinal permeability drive microRNAs, NLRP-3 inflammasome and liver fibrosis in a nutritional model of non-alcoholic steatohepatitis in adult male sprague dawley rats","volume":"13","author":"Longo","year":"2020","journal-title":"Clin Exp Gastroenterol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.redox.2017.03.006","article-title":"Butyrate induces ROS-mediated apoptosis by modulating miR-22\/SIRT-1 pathway in hepatic cancer cells","volume":"12","author":"Pant","year":"2017","journal-title":"Redox Biol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3389\/fphys.2019.00279","article-title":"Regulatory non-coding RNAs network in non-alcoholic fatty liver disease","volume":"10","author":"Sulaiman","year":"2019","journal-title":"Front Physiol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1136\/gutjnl-2020-322526","article-title":"MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases","volume":"70","author":"Wang","year":"2021","journal-title":"Gut."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3390\/nu13041281","article-title":"The combination of berberine, tocotrienols and coffee extracts improves metabolic profile and liver steatosis by the modulation of gut microbiota and hepatic miR-122 and miR-34a expression in mice","volume":"13","author":"Cossiga","year":"2021","journal-title":"Nutrients."},{"key":"B113","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12986-018-0323-6","article-title":"Amelioration of hepatic steatosis is associated with modulation of gut microbiota and suppression of hepatic miR-34a in Gynostemma pentaphylla (Thunb","volume":"15","author":"Jia","year":"2018","journal-title":"Nutr Metab."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19490976.2020.1840766","article-title":"Host miRNA-21 promotes liver dysfunction by targeting small intestinal Lactobacillus in mice","volume":"12","author":"Santos","year":"2020","journal-title":"Gut Microbes."},{"key":"B115","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1007\/s00125-017-4209-3","article-title":"Associations between hepatic miRNA expression, liver triacylglycerols and gut microbiota during metabolic adaptation to high-fat diet in mice","volume":"60","author":"Blasco-Baque","year":"2017","journal-title":"Diabetologia."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cellsig.2017.07.016","article-title":"MicroRNA-146a-5p attenuates liver fibrosis by suppressing profibrogenic effects of TGFbeta1 and lipopolysaccharide","volume":"39","author":"Zou","year":"2017","journal-title":"Cell Signal."},{"key":"B117","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/hep.31050","article-title":"Lipotoxic hepatocyte-derived exosomal MicroRNA 192-5p activates macrophages through rictor\/Akt\/Forkhead box transcription factor O1 signaling in nonalcoholic fatty liver disease","volume":"72","author":"Liu","year":"2020","journal-title":"Hepatology."},{"key":"B118","doi-asserted-by":"publisher","first-page":"45232","DOI":"10.1038\/srep45232","article-title":"Sex-dependent effects on gut microbiota regulate hepatic carcinogenic outcomes","volume":"7","author":"Xie","year":"2017","journal-title":"Sci Rep."},{"key":"B119","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nri2957","article-title":"MicroRNAs: the fine-tuners of Toll-like receptor signalling","volume":"11","author":"O'Neill","year":"2011","journal-title":"Nat Rev Immunol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.cell.2020.02.041","article-title":"Toll-like receptors and the control of immunity","volume":"180","author":"Fitzgerald","year":"2020","journal-title":"Cell."},{"key":"B121","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1365-2567.2009.03179.x","article-title":"Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific","volume":"129","author":"Wu","year":"2010","journal-title":"Immunology."},{"key":"B122","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1478-3231.2006.01254.x","article-title":"Human intrahepatic biliary epithelial cells function in innate immunity by producing IL-6 and IL-8 via the TLR4-NF-kappaB and -MAPK signaling pathways","volume":"26","author":"Yokoyama","year":"2006","journal-title":"Liver Int."},{"key":"B123","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/j.1478-3231.2010.02251.x","article-title":"Attenuation of toll-like receptor 2-mediated innate immune response in patients with alcoholic chronic liver disease","volume":"30","author":"Pimentel-Nunes","year":"2010","journal-title":"Liver Int."},{"key":"B124","doi-asserted-by":"publisher","first-page":"G15","DOI":"10.1152\/ajpgi.90512.2008","article-title":"Role of Toll-like receptors 2, 4, and 9 in mediating neutrophil dysfunction in alcoholic hepatitis","volume":"296","author":"Stadlbauer","year":"2009","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/hep.21138","article-title":"Differential liver sensitization to toll-like receptor pathways in mice with alcoholic fatty liver","volume":"43","author":"Gustot","year":"2006","journal-title":"Hepatology."},{"key":"B126","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/jcp.28293","article-title":"The induced decrease in TLR2 and TLR4 by cerebrolysin in the alcoholic liver of rats","volume":"218","author":"Mahmoudi","year":"2019","journal-title":"J Cell Physiol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/j.1530-0277.2011.01673.x","article-title":"The type of dietary fat modulates intestinal tight junction integrity, gut permeability, and hepatic toll-like receptor expression in a mouse model of alcoholic liver disease","volume":"36","author":"Kirpich","year":"2012","journal-title":"Alcohol Clin Exp Res."},{"key":"B128","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.chom.2019.11.001","article-title":"Roseburia spp. abundance associates with alcohol consumption in humans and its administration ameliorates alcoholic fatty liver in mice","volume":"27","author":"Seo","year":"2020","journal-title":"Cell Host Microbe."},{"key":"B129","doi-asserted-by":"publisher","first-page":"G30","DOI":"10.1152\/ajpgi.00031.2015","article-title":"TLR2 and TLR9 contribute to alcohol-mediated liver injury through induction of CXCL1 and neutrophil infiltration","volume":"309","author":"Roh","year":"2015","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jcmgh.2019.09.002","article-title":"Divergent roles of kupffer cell TLR2\/3 signaling in alcoholic liver disease and the protective role of eGCG","volume":"9","author":"Luo","year":"2020","journal-title":"Cell Mol Gastroenterol Hepatol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1155\/2010\/710381","article-title":"Toll-like receptors in the pathogenesis of alcoholic liver disease","author":"Petrasek","year":"2010","journal-title":"Gastroenterol Res Pract."},{"key":"B132","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1189\/jlb.3A0716-310R","article-title":"Alcohol-induced miR-155 and HDAC11 inhibit negative regulators of the TLR4 pathway and lead to increased LPS responsiveness of Kupffer cells in alcoholic liver disease","volume":"102","author":"Bala","year":"2017","journal-title":"J Leukoc Biol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.3390\/nu9111220","article-title":"Nonalcoholic fatty liver disease is exacerbated in high-fat diet-fed gnotobiotic mice by colonization with the gut microbiota from patients with nonalcoholic steatohepatitis","volume":"9","author":"Chiu","year":"2017","journal-title":"Nutrients."},{"key":"B134","doi-asserted-by":"publisher","first-page":"7381","DOI":"10.3748\/wjg.v20.i23.7381","article-title":"Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease","volume":"20","author":"Miura","year":"2014","journal-title":"World J Gastroenterol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"100117","DOI":"10.1016\/j.jhepr.2020.100117","article-title":"Imaging and immunometabolic phenotyping uncover changes in the hepatic immune response in the early phases of NAFLD","volume":"2","author":"Diniz","year":"2020","journal-title":"JHEP Rep."},{"key":"B136","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/hep.26081","article-title":"Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice","volume":"57","author":"Miura","year":"2013","journal-title":"Hepatology."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1111\/jgh.12924","article-title":"Role of serum toll-like receptors 2 and 4 in non-alcoholic steatohepatitis and liver fibrosis","volume":"30","author":"Cengiz","year":"2015","journal-title":"J Gastroenterol Hepatol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.lfs.2018.08.017","article-title":"Gut inflammation exacerbates hepatic injury in the high-fat diet induced NAFLD mouse: attention to the gut-vascular barrier dysfunction","volume":"209","author":"Cheng","year":"2018","journal-title":"Life Sci."},{"key":"B139","doi-asserted-by":"publisher","first-page":"e0152786","DOI":"10.1371\/journal.pone.0152786","article-title":"Adipocytes as a link between gut microbiota-derived flagellin and hepatocyte fat accumulation","volume":"11","author":"Munukka","year":"2016","journal-title":"PLoS ONE."},{"key":"B140","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.cmet.2015.09.028","article-title":"Microbiota-Dependent Hepatic Lipogenesis Mediated by Stearoyl CoA Desaturase 1 (SCD1) promotes metabolic syndrome in TLR5-Deficient mice","volume":"22","author":"Singh","year":"2015","journal-title":"Cell Metab."},{"key":"B141","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jcmgh.2016.04.007","article-title":"Hepatocyte Toll-Like receptor 5 promotes bacterial clearance and protects mice against high-fat diet-induced liver disease","volume":"2","author":"Etienne-Mesmin","year":"2016","journal-title":"Cell Mol Gastroenterol Hepatol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1042\/CS20160838","article-title":"TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival","volume":"131","author":"Mridha","year":"2017","journal-title":"Clin Sci (Lond)."},{"key":"B143","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1172\/JCI83885","article-title":"Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9","volume":"126","author":"Garcia-Martinez","year":"2016","journal-title":"J Clin Invest."},{"key":"B144","doi-asserted-by":"publisher","first-page":"5878","DOI":"10.3390\/ijms17111878","article-title":"Increased expression profile and functionality of tlr6 in peripheral blood mononuclear cells and hepatocytes of morbidly obese patients with non-alcoholic fatty liver disease","volume":"17","author":"Arias-Loste","year":"2016","journal-title":"Int J Mol Sci."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1161\/CIRCRESAHA.120.317362","article-title":"Gut microbiota-associated activation of TLR5 induces apolipoprotein A1 production in the liver","volume":"127","author":"Yiu","year":"2020","journal-title":"Circ Res."},{"key":"B146","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/imm.13251","article-title":"TLR5 activation in hepatocytes alleviates the functional suppression of intrahepatic CD8(+) T cells","volume":"161","author":"Yan","year":"2020","journal-title":"Immunology."},{"key":"B147","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/00042737-200303000-00011","article-title":"Differential expression of toll-like receptors 2 and 4 in patients with liver cirrhosis","volume":"15","author":"Manigold","year":"2003","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1136\/gutjnl-2015-311224","article-title":"Gut microbial translocation corrupts myeloid cell function to control bacterial infection during liver cirrhosis","volume":"66","author":"Hackstein","year":"2017","journal-title":"Gut."},{"key":"B149","doi-asserted-by":"publisher","first-page":"11504","DOI":"10.1074\/jbc.M115.709048","article-title":"Toll-like receptor 4 on macrophage promotes the development of steatohepatitis-related hepatocellular carcinoma in mice","volume":"291","author":"Miura","year":"2016","journal-title":"J Biol Chem."},{"key":"B150","first-page":"12738","article-title":"miR-143 down-regulates TLR2 expression in hepatoma cells and inhibits hepatoma cell proliferation and invasion","volume":"8","author":"Liu","year":"2015","journal-title":"Int J Clin Exp Pathol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"111560","DOI":"10.1016\/j.biopha.2021.111560","article-title":"Probiotics-rich emulsion improves insulin signalling in Palmitate\/Oleate-challenged human hepatocarcinoma cells through the modulation of Fetuin-A\/TLR4-JNK-NF-kappaB pathway","volume":"139","author":"Mularczyk","year":"2021","journal-title":"Biomed Pharmacother."},{"key":"B152","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nri1745","article-title":"Dectin-1: a signalling non-TLR pattern-recognition receptor","volume":"6","author":"Brown","year":"2006","journal-title":"Nat Rev Immunol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/j.celrep.2015.10.058","article-title":"Dectin-1 regulates hepatic fibrosis and hepatocarcinogenesis by suppressing TLR4 signaling pathways","volume":"13","author":"Seifert","year":"2015","journal-title":"Cell Rep."},{"key":"B154","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.jhep.2006.07.022","article-title":"Biliary candida infections in primary sclerosing cholangitis","volume":"45","author":"Kulaksiz","year":"2006","journal-title":"J Hepatol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"4718","DOI":"10.4049\/jimmunol.177.7.4718","article-title":"Galectin-3 induces death of Candida species expressing specific beta-1,2-linked mannans","volume":"177","author":"Kohatsu","year":"2006","journal-title":"J Immunol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.4049\/jimmunol.181.4.2781","article-title":"Galectin-3 is a negative regulator of lipopolysaccharide-mediated inflammation","volume":"181","author":"Li","year":"2008","journal-title":"J Immunol."},{"key":"B157","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.4049\/jimmunol.177.7.4679","article-title":"Specific recognition of Candida albicans by macrophages requires galectin-3 to discriminate Saccharomyces cerevisiae and needs association with TLR2 for signaling","volume":"177","author":"Jouault","year":"2006","journal-title":"J Immunol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/1751-2980.12918","article-title":"Role of NLRP3 inflammasome in liver disease","volume":"21","author":"Al Mamun","year":"2020","journal-title":"J Dig Dis."},{"key":"B159","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jceh.2013.03.225","article-title":"Gut-liver axis: role of inflammasomes","volume":"3","author":"Bawa","year":"2013","journal-title":"J Clin Exp Hepatol."},{"key":"B160","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature10809","article-title":"Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity","volume":"482","author":"Henao-Mejia","year":"2012","journal-title":"Nature."},{"key":"B161","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/hep.28456","article-title":"Interleukin-1 and inflammasomes in alcoholic liver disease\/acute alcoholic hepatitis and nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"64","author":"Tilg","year":"2016","journal-title":"Hepatology."},{"key":"B162","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.3389\/fimmu.2017.01728","article-title":"Relevance of the NLRP3 inflammasome in the pathogenesis of chronic liver disease","volume":"8","author":"Wu","year":"2017","journal-title":"Front Immunol."},{"key":"B163","doi-asserted-by":"publisher","first-page":"37657","DOI":"10.18632\/oncotarget.17489","article-title":"Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development","volume":"8","author":"He","year":"2017","journal-title":"Oncotarget."},{"key":"B164","doi-asserted-by":"publisher","first-page":"13241","DOI":"10.3390\/cells8111324","article-title":"The role of gut-derived microbial antigens on liver fibrosis initiation and progression","volume":"8","author":"Chen","year":"2019","journal-title":"Cells."},{"key":"B165","doi-asserted-by":"publisher","first-page":"dmm048922","DOI":"10.1242\/dmm.048922","article-title":"Modulation of serotonin in the gut-liver neural axis ameliorates the fatty and fibrotic changes in non-alcoholic fatty liver","volume":"14","author":"Ko","year":"2021","journal-title":"Dis Model Mech."},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31708","article-title":"The use of rifaximin in patients with cirrhosis","author":"Caraceni","year":"2021","journal-title":"Hepatology"},{"key":"B167","doi-asserted-by":"publisher","first-page":"5589","DOI":"10.3390\/ijms21155589","article-title":"Effective combination therapy of angiotensin-ii receptor blocker and rifaximin for hepatic fibrosis in rat model of nonalcoholic steatohepatitis","volume":"21","author":"Fujinaga","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B168","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.jhep.2008.01.035","article-title":"Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin","volume":"48","author":"Bergheim","year":"2008","journal-title":"J Hepatol."},{"key":"B169","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.3748\/wjg.v23.i25.4491","article-title":"Eubiotic properties of rifaximin: disruption of the traditional concepts in gut microbiota modulation","volume":"23","author":"Ponziani","year":"2017","journal-title":"World J Gastroenterol."},{"key":"B170","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1097\/MEG.0000000000001232","article-title":"Rifaximin in nonalcoholic fatty liver disease: hit multiple targets with a single shot","volume":"30","author":"Abdel-Razik","year":"2018","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B171","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S2468-1253(19)30320-6","article-title":"Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"5","author":"Pose","year":"2020","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B172","doi-asserted-by":"publisher","first-page":"e133410","DOI":"10.1172\/jci.insight.133410","article-title":"Microbial functional change is linked with clinical outcomes after capsular fecal transplant in cirrhosis","volume":"4","author":"Bajaj","year":"2019","journal-title":"JCI Insight."},{"key":"B173","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s00394-018-1721-2","article-title":"Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial","volume":"58","author":"Bomhof","year":"2019","journal-title":"Eur J Nutr."},{"key":"B174","doi-asserted-by":"publisher","first-page":"41","DOI":"10.15403\/jgld.2014.1121.271.kby","article-title":"A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial","volume":"27","author":"Kobyliak","year":"2018","journal-title":"J Gastrointestin Liver Dis."},{"key":"B175","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-019-0495-2","article-title":"Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study","volume":"25","author":"Depommier","year":"2019","journal-title":"Nat Med."},{"key":"B176","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12876-015-0400-5","article-title":"Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol","volume":"15","author":"Lambert","year":"2015","journal-title":"BMC Gastroenterol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet."},{"key":"B178","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1016\/j.cgh.2014.04.038","article-title":"The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease","volume":"12","author":"Safadi","year":"2014","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B179","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S2468-1253(19)30184-0","article-title":"Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial","volume":"4","author":"Traussnigg","year":"2019","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-323608","article-title":"Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial","author":"Mingrone","year":"2021","journal-title":"Gut."},{"key":"B181","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.jhep.2020.01.017","article-title":"Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis","volume":"72","author":"Bajaj","year":"2020","journal-title":"J Hepatol."},{"key":"B182","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.jhep.2016.11.008","article-title":"Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice","volume":"66","author":"Ferrere","year":"2017","journal-title":"J Hepatol."},{"key":"B183","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1136\/gutjnl-2019-318320","article-title":"Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time","volume":"69","author":"de Groot","year":"2020","journal-title":"Gut."},{"key":"B184","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","article-title":"Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial","volume":"114","author":"Allegretti","year":"2019","journal-title":"Am J Gastroenterol."},{"key":"B185","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1002\/hep.31496","article-title":"A randomized clinical trial of fecal microbiota transplant for alcohol use disorder","volume":"73","author":"Bajaj","year":"2021","journal-title":"Hepatology."},{"key":"B186","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jhep.2008.05.025","article-title":"Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells","volume":"49","author":"Ma","year":"2008","journal-title":"J Hepatol."},{"key":"B187","doi-asserted-by":"publisher","first-page":"E1306","DOI":"10.1073\/pnas.1518189113","article-title":"Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice","volume":"113","author":"Li","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"key":"B188","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1136\/gutjnl-2016-313432","article-title":"Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease","volume":"67","author":"Grander","year":"2018","journal-title":"Gut."},{"key":"B189","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science."},{"key":"B190","doi-asserted-by":"publisher","first-page":"558525","DOI":"10.3389\/fphar.2020.558525","article-title":"Inulin exerts beneficial effects on non-alcoholic fatty liver disease via modulating gut microbiome and suppressing the lipopolysaccharide-Toll-Like receptor 4-Mpsi-NUCLEAR FACTOR-kappaB-Nod-like receptor protein 3 pathway via gut-liver axis in mice","volume":"11","author":"Bao","year":"2020","journal-title":"Front Pharmacol."},{"key":"B191","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1007\/s00394-020-02248-7","article-title":"Effects of synbiotic consumption on lipid profile: a systematic review and meta-analysis of randomized controlled clinical trials","volume":"59","author":"Hadi","year":"2020","journal-title":"Eur J Nutr."},{"key":"B192","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J Hepatol."},{"key":"B193","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41575-020-00404-2","article-title":"The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer","volume":"18","author":"Sun","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B194","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.jhep.2019.06.017","article-title":"FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis","volume":"71","author":"Sorribas","year":"2019","journal-title":"J Hepatol."},{"key":"B195","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J Hepatol."},{"key":"B196","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jhep.2020.01.011","article-title":"Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure","volume":"73","author":"Engelmann","year":"2020","journal-title":"J Hepatol."},{"key":"B197","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.3390\/cells10061562","article-title":"Eritoran attenuates hepatic inflammation and fibrosis in mice with chronic liver injury","volume":"10","author":"Hsieh","year":"2021","journal-title":"Cells."},{"key":"B198","doi-asserted-by":"publisher","first-page":"A125","DOI":"10.1136\/gutjnl-2012-302514b.128","article-title":"Effects of oral nanoporous carbon therapy in leptin null mice as a model of non-alcoholic steatohepatitis","volume":"61","author":"Macnaughtan","year":"2012","journal-title":"Gut."},{"key":"B199","doi-asserted-by":"publisher","first-page":"17075","DOI":"10.1038\/nmicrobiol.2017.75","article-title":"The path towards microbiome-based metabolite treatment","volume":"2","author":"Suez","year":"2017","journal-title":"Nat Microbiol."},{"key":"B200","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3389\/fmicb.2019.00477","article-title":"A novel postbiotic from Lactobacillus rhamnosus GG with a beneficial effect on intestinal barrier function","volume":"10","author":"Gao","year":"2019","journal-title":"Front Microbiol."},{"key":"B201","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13104-021-05568-x","article-title":"Evaluation of E. coli Nissle1917 derived metabolites in modulating key mediator genes of the TLR signaling pathway","volume":"14","author":"Damoogh","year":"2021","journal-title":"BMC Res Notes."},{"key":"B202","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/nbt.4222","article-title":"Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria","volume":"36","author":"Isabella","year":"2018","journal-title":"Nat Biotechnol."},{"key":"B203","doi-asserted-by":"publisher","first-page":"au7975","DOI":"10.1126\/scitranslmed.aau7975","article-title":"An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans","volume":"11","author":"Kurtz","year":"2019","journal-title":"Sci Transl Med."},{"key":"B204","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1136\/gutjnl-2018-317232","article-title":"Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice","volume":"68","author":"Hendrikx","year":"2019","journal-title":"Gut."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.725390\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:44:46Z","timestamp":1632789886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.725390\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":204,"alternative-id":["10.3389\/fmed.2021.725390"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.725390","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,28]]},"article-number":"725390"}}